Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, ...

abrdn plc lifted its position in Scholar Rock by 28.2% during the third quarter. abrdn plc now owns 748,489 shares of the company’s stock valued at $5,995,000 after buying an additional 164,715 ...

Exchange Traded Concepts LLC lessened its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 81.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 18,887 shares ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

Deep in the Colombian Amazon region of Serrania De La Lindosa, a roughly 12-mile stretch of rock is covered in a vast ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and ...